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Background: Thrombolysis, with or without thrombectomy, for acute ischaemic stroke
is associated with an increased risk of intracranial bleeding. We assessed whether
treatment with glyceryl trinitrate (GTN), a nitric oxide donor, may influence the associated
bleeding risk.
Methods: We searched for completed randomized controlled trials of GTN vs. no
GTN in acute ischaemic stroke with data on reperfusion treatments (thrombolysis and/or
thrombectomy). The primary efficacy outcome was functional status as assessed by the
modified Rankin Scale (mRS) at day 90; the primary safety outcome was intracranial
bleeding. Secondary safety outcomes included symptomatic intracranial hemorrhage
and haemorrhagic transformation of infarction. Individual patient data were pooled and
meta-analysis performed using ordinal or binary logistic regression with adjustment
for trial and prognostic variables both overall and in those randomized within 6 h of
symptom onset.
Results: Three trials met the eligibility criteria. Of 715 patients with ischaemic stroke
who underwent thrombolysis (709, >99%) or thrombectomy (24, 3.4%), 357 (49.9%)
received GTN and 358 (50.1%) received no GTN. Overall, there was no difference in the
distribution of the mRS at day 90 between GTN vs. no GTN (OR 0.94, 95% CI 0.72–1.23;
p = 0.65); similarly, there was no difference in intracranial hemorrhage rates between
treatment groups (OR 0.90, 95% CI 0.43–1.89; p = 0.77). In those randomized to GTN
vs. no GTN within 6 h of symptom onset, there were numerically fewer bleeding events,
but these analyses did not reach statistical significance.
Conclusions: In ischaemic stroke patients treated predominantly with thrombolysis,
transdermal GTN was safe, but did not influence functional outcome at 90 days.
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INTRODUCTION
Thrombolysis with alteplase for acute ischaemic stroke is an
efficacious treatment if given within 4.5 h of onset, but is
associated with an increased risk of symptomatic intracranial
hemorrhage (sICH: 6.8% thrombolysis vs. 1.3% placebo) (1).
In the context of large vessel occlusion of the anterior cerebral
circulation, thrombectomy is highly effective at improving
clinical outcomes when performed within 6 h of onset (2),
and upto 24 h in those with perfusion mismatch (3). In trials
including patients who received alteplase, there was no difference
in sICH rates between those randomized to thrombectomy and
no thrombectomy (2). Further, a recent trial assessing tPA +
thrombectomy vs. thrombectomy alone, found no difference in
sICH rates (4).
Raised blood pressure (BP) in those undergoing
thrombolysis has been associated with increased risk of
haemorrhagic transformation of infarction (HTI) and sICH.
The ENCHANTED-BP trial found that intensive lowering of BP
in those undergoing thrombolysis did not improve functional
outcome but did reduce the rate of sICH as compared with
guideline BP management (5). It is unclear whether specific BP
agents exert effects that may augment reperfusion strategies. The
nitric oxide donor, glyceryl trinitrate (GTN), has been associated
with improved clinical outcomes when administered as a patch
within 6 h of stroke onset in a subgroup of the large ENOS trial
(6). However, when administered in the pre-hospital setting
within 4 h of onset, GTN had a neutral effect on functional
outcome (7). Data from a small pilot study in the ambulance
found that treatment with GTN was associated with a tendency
toward increased rates of thrombolysis compared with no GTN,
suggesting that GTN may prime patients for thrombolysis by
lowering their BP into the treatment range (8). Little is known
about whether GTN influences the bleeding risk associated with
reperfusion treatments. Here, we assessed the effect of GTN
in those undergoing reperfusion therapies and the associated
bleeding risk.
METHODS
The study was registered with PROSPERO (CRD42020193427)
and followed PRISMA guidance (Supplementary Table 1).
Search Strategy and Selection Criteria
We searched EMBASE, PubMed, and Cochrane Library for
randomized controlled trials of GTN in adults with acute stroke
and data on reperfusion treatments, including thrombolysis or
thrombectomy, using the search terms: “stroke” OR “cerebral
ischaemia,” AND “glyceryl trinitrate” OR “nitroglycerin,” AND
“randomized,” OR “randomized.” Non-randomized studies were
Abbreviations: ECB, Extracranial bleeding; ENOS, Efficacy of nitric oxide in
stroke; HTI, transformation of infarction; MEH, Major extracranial hemorrhage;
mRS, modified Rankin Scale; RIGHT, Rapid intervention with glyceryl trinitrate in
hypertensive stroke trial; RIGHT-2, Rapid intervention with glyceryl trinitrate in
hypertensive stroke trial-2; sICH, symptomatic intracranial hemorrhage.
excluded. We aimed to perform an individual patient data meta-
analysis of the trials found, focusing on acute ischaemic stroke
patients treated with reperfusion strategies. Participants with
available data on reperfusion therapy and modified Rankin Scale
(mRS) score at 90 days were eligible for inclusion.
Search results were screened, abstracts reviewed and full-text
manuscripts assessed for inclusion criteria by one author (JPA).
We assessed risk of bias of the included studies using Cochrane’s
“risk of bias” tool as high, low or unclear risk across the following
elements: random sequence generation; allocation concealment;
blinding of participants and personnel; blinding of outcome
assessment; incomplete outcome data; selective reporting; and
other sources of bias (9).
The chief investigator of the included studies was approached
to share individual patient data for use in the meta-analysis.
Ethical approval was obtained for each of the included trials
and informed consent was received from participants or their
legal representative.
Clinical Outcomes
The primary efficacy outcome was functional outcome measured
using the mRS at day 90; a seven level ordinal scale ranging from
0 = no symptoms, through increasing levels of dependency, to 6
= death.
The primary safety outcome was intracranial hemorrhage;
secondary safety outcomes focused on bleeding using accepted
definitions of sICH, HTI, extracranial bleeding (ECB), and major
extracranial hemorrhage (MEH). In the included trials, imaging
data were collected at sites and adjudicated centrally by trained
neuroradiologists using a set proforma (10). Safety data on death
were also collected at day 7 and day 90.
Outcomes were assessed overall across the total population of
the included trials, and in those participants randomized to GTN
vs. no GTN within 6 h of stroke onset in order to assess the effect
of GTN in close proximity to reperfusion therapies.
Data Analysis
The individual patient databases of the included trials were
merged by LJW. Participants with a non-ischaemic stroke
diagnosis, or those who did not receive reperfusion therapies,
were removed from the dataset. Data on recruitment, age,
sex, baseline mRS, prior medical problems, baseline National
Institutes for Health Stroke Scale (NIHSS), stroke etiology,
stroke syndrome, stroke type, time to randomization, baseline
hemodynamics, mRS at day 90, death at day 7, and 90,
intracranial bleeding, HTI, sICH, ECB, and MEH were extracted.
Data are number (%), mean (standard deviation, SD), median
[interquartile range]. Baseline characteristics were compared
across trials by Chi-square test, Kruskal–Wallis test, or one-
way ANOVA as appropriate. Data between treatment groups
were assessed by intention-to-treat. Ordinal or binary logistic
regression was used to assess differences in clinical outcomes
between treatment groups with resultant odds ratio (OR) with
95% confidence intervals (CI) provided. Analyses were adjusted
for prognostic variables including age, sex, baseline mRS,
baseline NIHSS, baseline systolic BP, time to randomization,
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and trial. Subgroup analyses were performed by adding an
interaction term to an unadjusted ordinal logistic regression
model. Significance was set at p < 0.05. Analyses were




Three trials met the inclusion criteria: RIGHT (8), ENOS
(11), and RIGHT-2 (7) trials (Supplementary Figure 1). All
three trials assessed transdermal GTN 5mg patches vs. no
patch, but varied in design and delivery. RIGHT (n = 41)
and RIGHT-2 (n = 1149) were both pre-hospital paramedic-
delivered trials that randomized patients with presumed stroke
to transdermal GTN or no GTN within 4 h of onset.
There were 6 further days of trial treatment in hospital in
RIGHT and 3 further days in RIGHT-2. In contrast, ENOS
(n = 4,011) was a large in-hospital trial that randomized
participants with stroke within 48 h of onset to GTN or
no GTN given for 7 days. Therefore, patients in RIGHT
and RIGHT-2 received GTN or no GTN in the ambulance
prior to reperfusion therapies in hospital, whilst most ENOS
participants with ischaemic stroke were randomized after
the thrombolysis window. All participants underwent baseline
neuroimaging. Follow-up imaging was stipulated as part of
the RIGHT-2 trial at day 2 and as clinically indicated in
all three trials e.g., 24 h post-thrombolysis/thrombectomy. All
neuroimaging scans were adjudicated centrally by trained
neuroradiologists. All participants had data extracted for the
clinical outcomes specified, where available. Further details
pertaining to the conduct and results of the individual trials are
published (7, 8, 11).
Risk of Bias of Included Studies
Full details are provided in a “risk of bias” table
(Supplementary Table 2) and associated figures
(Supplementary Figures 2, 3). In summary, all three trials
had low risk of bias in relation to the elements assessed except for
blinding of participants and personnel (performance bias), which
was an unclear risk of bias in all three included studies. There
was no placebo patch available in any of the included studies
and therefore a gauze dressing was applied over the GTN patch
or equivalent area of skin in ENOS (11) and RIGHT (8), whilst
in RIGHT-2 (7) a Duoderm dressing was placed on the skin of
those randomized to no GTN with a gauze dressing on top. As
such, participants were blinded but investigators applying the
patch/dressing were not.
Baseline Characteristics
Data were available for 715 participants (GTN 357, no GTN
358) with acute ischaemic stroke who underwent reperfusion
therapies from the three included studies. Data on reperfusion
treatment were available in 414 patients recruited into ENOS
(from 2003 to 2013), 10 patients in RIGHT (2010–2011)
and 291 patients in RIGHT-2 (2015–2018) (Table 1). Overall,
the average age was 72 years old, 45% were female, 62%
had hypertension, and 21% atrial fibrillation (AF). The mean
NIHSS score was 12.5 and median GCS 15. A substantial
proportion of participants (36%) were deemed to have a
cardioembolic etiology for their stroke. Baseline BP was 162
/ 87 mmHg, with a median time to randomization of 4.9 h.
The vast majority underwent thrombolysis (709, 99%) with 24
(3.4%) patients being treated with thrombectomy. Of the 24
participants who underwent thrombectomy, six did not receive
thrombolysis (Table 1).
Across the three trials the participants were older and baseline
mRS was higher in RIGHT and RIGHT-2 than in ENOS
(Table 1). Similarly, AF rates differed across the trials with
a higher proportion in RIGHT-2. Median GCS was lower in
RIGHT-2 than ENOS and RIGHT. Large vessel and small vessel
stroke etiologies were more common in ENOS than RIGHT
or RIGHT-2. Baseline BP and heart rate also varied across the
trials. Due to the different randomization periods across the
trials, participants were randomized at around 1 h after symptom
onset in RIGHT and RIGHT-2, and at 22 h in ENOS. The 24
patients who received thrombectomy were all from the RIGHT-2
trial (Table 1).
Clinical Outcomes
Overall, the distribution of the mRS at day 90 did not differ
by randomization to GTN or no GTN in unadjusted and
adjusted analyses: adjusted OR 0.94, 95% CI 0.72–1.23, p = 0.65
(Table 2 and Figure 1). There were 32 (4.5%) intracranial bleeds,
of which 12 (1.7%) were sICH. There were no differences in
bleeding rates between the GTN and no GTN groups. There were
numerically fewer HTIs in the GTN than no GTN groups (8 vs.
11) although this was not statistically significant. ECB and MEH
were uncommon and did not differ by randomized treatment. No
differences between GTN groups were noted for death at day 7 or
day 90 (Table 2).
In those randomized to GTN or no GTN within 6 h of onset,
there was a non-significant tendency toward improved 90 day
functional outcome in both unadjusted and adjusted analyses: OR
0.81, 95% CI 0.56 to 1.18, p = 0.27 (Table 2, Figure 2). Similarly,
there were numerically fewer intracranial bleeds, sICH, and HTI
in those randomized to GTN than no GTN, but none of these
analyses reached statistical significance. Rates of ECB and MEH,
and death at day 7 and 90 did not differ between treatment
groups (Table 2).
Subgroup Analyses
In an unadjusted ordinal logistic regression model there
were no significant interactions noted between subgroups and
randomization to GTN vs. no GTN (Figure 3). The baseline
systolic BP subgroup interaction narrowly missed statistical
significance (p = 0.053), with a suggestion that treatment
with GTN in participants with increasing systolic BP may be
associated with tendencies toward improved functional outcome
at 90 days. Further, treatment with GTN in those with baseline
systolic BP<140 mmHgmay be associated with worse functional
outcome (Figure 3).
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TABLE 1 | Baseline characteristics of ischaemic stroke participants who underwent reperfusion strategies by trial.
All ENOS RIGHT RIGHT-2 p
Number of patients 715 414 10 291
Years of recruitment, range 2003–2018 2003–2013 2010–2011 2015–2018 –
Median, [IQR] 2013 [2011, 2017] 2012 [2010, 2012] 2010 [2010–2011] 2017 [2016–2017] <0.001
Age (years) 72.4 (11.6) 71.0 (11.4) 78.2 (5.9) 74.2 (11.8) <0.001
Sex, male (%) 393 (55.0) 239 (57.7) 7 (70.0) 147 (50.5) 0.10
mRS [/6] 0 [0, 1] 0 [0, 0] 0 [0, 1] 0 [0, 1] <0.001
Medical history (%)
Hypertension 444 (62.1) 265 (64.0) 7 (70.0) 172 (59.1) 0.37
Diabetes mellitus 118 (16.5) 57 (13.8) 2 (20.0) 59 (20.3) 0.07
Atrial fibrillation 136 (20.6) 73 (17.6) 2 (20.0) 61 (25.7) 0.048
Stroke 88 (12.3) 43 (10.4) 1 (10.0) 44 (15.1) 0.17
TIA 92 (13.1) 53 (13.2) 3 (30.0) 36 (12.4) 0.27
IHD 103 (14.5) 59 (14.5) 0 44 (15.1) 0.41
PAD 22 (3.1) 18 (4.5) 0 4 (1.4) 0.058
Smoking, current 139 (19.4) 85 (20.5) 4 (40.0) 50 (17.2) 0.14
Alcohol >21 units per week 51 (7.1) 33 (8.0) 0 18 (6.2) 0.45
Qualifying event (%)
Ischaemic stroke 714 (99.9) 414 (100.0) 10 (100.0) 290 (99.7) 0.48
TIA 0 0 0 1 (0.3) 0.48
NIHSS (/42) 12.5 (6.0) 12.2 (5.3) 11.7 (5.3) 13.0 (7.0) 0.17
GCS [/15] 15 [13,15] 15 [14,15] 15 [13,15] 14 [12,15] <0.001
TOAST classification (%)
Cardioembolic 252 (35.7) 136 (32.9) 5 (50.0) 111 (39.4) 0.14
Large vessel 157 (22.2) 106 (25.6) 2 (20.0) 49 (17.4) 0.037
Small vessel 121 (17.1) 85 (20.5) 1 (10.0) 35 (12.4) 0.017
Other 179 (25.4) 88 (21.3) 2 (20.0) 89 (31.6) 0.008
Hemodynamics
BP, Systolic (mmHg) 161.6 (19.2) 163.1 (16.0) 176.5 (27.7) 158.9 (22.4) 0.001
BP, Diastolic (mmHg) 87.2 (14.1) 85.9 (12.4) 92.5 (22.8) 88.7 (15.9) 0.019
Heart rate 78.8 (18.5) 76.6 (15.7) 84.7 (22.6) 81.8 (21.3) 0.001
Time to randomization [hours] 4.9 [1.1, 23.5] 21.7 [7.6, 28.7] 1.1 [0.7, 2.1] 1.0 [0.7, 1.4] <0.001
Thrombolysis (%) 709 (99.2) 414 (100.0) 10 (100.0) 285 (97.9) 0.012
Thrombectomy (%) 24 (3.4) - - 24 (8.5) -
Data are number (%), mean (standard deviation, SD), median [interquartile range, IQR]; comparison across trials by Chi-square test, Kruskal–Wallis test, or one-way ANOVA.
BP, blood pressure; ENOS, Efficacy of nitric oxide in stroke trial; GCS, Glasgow coma score; IHD, ischaemic heart disease; mRS, modified Rankin Scale; NIHSS, National Institutes for
Health Stroke Scale; PAD, peripheral arterial disease; RIGHT, Rapid intervention with glyceryl trinitrate in hypertensive stroke trial; TIA, transient ischaemic attack.
DISCUSSION
In this individual patient data meta-analysis of trials assessing
transdermal GTN vs. no GTN in acute ischaemic stroke patients
who underwent reperfusion therapies (>99% thrombolysis),
treatment with GTN was safe but did not influence functional
outcome at 90 days. Bleeding complications after reperfusion
therapies were infrequent and not influenced by GTN treatment
overall. However, in those randomized to GTN vs. no GTN
within 6 h of onset there was a tendency toward improved
functional outcome at 90 days and reduced rates of intracranial
haemorrhagic complications following reperfusion therapies,
but these findings did not reach statistical significance.
Randomization to GTN in those with higher systolic BP may be
associated with a tendency toward improved functional outcome.
BP lowering in patients with acute ischaemic stroke is
primarily reserved for patients with BP >185/110 mmHg who
are otherwise eligible for thrombolysis (12). There is some
evidence to suggest that in the context of large vessel occlusion,
intensive lowering of elevated BP may be harmful (13). However,
a U-shaped association with outcome was noted in the MR
CLEAN registry with both high and low levels of baseline
systolic BP being associated with worse clinical outcomes, whilst
increasing systolic BP was associated with increased rates of
sICH (14). Although there were too few thrombectomy patients
in the current study to add to this evidence base, transdermal
GTN was safe and did not worsen clinical outcomes nor affect
the occurrence of haemorrhagic complications in a population
predominantly treated with thrombolysis. This is in keeping with
the overall results of prior GTN in acute stroke trials to date; GTN
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TABLE 2 | Clinical outcomes of acute ischaemic stroke patients who underwent
reperfusion strategies by GTN vs. no GTN.
Overall GTN No GTN OR (95% CI) p
N (%) 357 (49.9) 358 (50.1)
Primary efficacy
outcome
mRS at day 90
[/6]–adjusted
3 [2,5] 3 [2,5] 0.94 (0.72, 1.23) 0.65





15 (4.2) 17 (4.7) 0.90 (0.43, 1.89) 0.77
Secondary
safety outcomes
sICH (%) 6 (1.7) 6 (1.7) 1.01 (0.31, 3.28) 0.99
HTI (%) 8 (2.2) 11 (3.1) 0.74 (0.29, 1.91) 0.53
ECB (%) 2 (0.6) 3 (0.8) 0.62 (0.10, 3.86) 0.61
MEH (%) 1 (0.3) 1 (0.3) 1.55 (0.08, 31.60) 0.78
Death
By day 7 (%) 14 (3.9) 13 (3.7) 1.21 (0.52, 2.80) 0.66
By day 90 (%) 57 (16.0) 57 (15.9) 1.03 (0.64, 1.64) 0.91
Randomized
<6 h
N (%) 206/357 (57.7) 183/358 (51.1)
Primary
outcome
mRS at day 90
[/6]–adjusted
3 [1,5] 3 [2,5] 0.81 (0.56, 1.18) 0.27





9 (4.4) 14 (7.7) 0.60 (0.24, 1.48) 0.27
Secondary
safety outcomes
sICH (%) 3 (1.5) 4 (2.2) 0.74 (0.16, 3.52) 0.70
HTI (%) 5 (2.4) 10 (5.5) 0.46 (0.15, 1.41) 0.17
ECB (%) 1 (0.5) 2 (1.1) 0.35 (0.02, 5.79) 0.47
MEH (%) 0 0 – –
Death
By day 7 (%) 4 (2.0) 3 (1.7) 1.05 (0.21, 5.26) 0.95
By day 90 (%) 32 (15.5) 32 (17.5) 0.86 (0.44, 1.69) 0.67
Data are number (%), odds ratio (OR), hazard ratio (HR) with 95% confidence intervals (CI)
using ordinal or binary logistic regression.
CI, confidence interval; ECB, extracranial bleeding; GTN, glyceryl trinitrate; HR, Hazard
ratio; HTI, haemorrhagic transformation of infarction; mRS, modified Rankin Scale; OR,
odds ratio; sICH, symptomatic intracranial hemorrhage.
Adjusted for age, sex, baseline mRS, baseline NIHSS, baseline systolic BP, time to
randomization, and trial.
lowers BP, is safe but does not influence functional outcome at 90
days (7, 15). NO has significant antiplatelet properties, but NO
donorsmay differ in their clinical antiplatelet effects: for example,
GTN, an organic NO donor, may have antiplatelet properties in
vitro (16) but did not in vivo in stroke patients (17); in contrast,
sodium nitroprusside, an inorganic NO donor, has both in vitro
and in vivo antiplatelet effects (18). Further, GTN may interrupt
the early vasoconstrictory phase in hemorrhage (19), thus leading
to more severe bleeding. In a subgroup analysis involving the
intracerebral hemorrhage patients recruited in the RIGHT-2 trial,
there was a tendency toward worse clinical outcomes in those
randomized to GTN vs. no GTN (20). However, this was a small
subgroup of the RIGHT-2 trial and the findings may represent
undetected baseline imbalances. Reassuringly, in the present
meta-analysis there were few bleeding events and we did not
see any signal of increased haemorrhagic complications. Instead,
there was a suggestion that GTN administered within 6 h of
symptom onset in those undergoing reperfusion treatments may
be associated with fewer bleeding complications, but this did not
reach statistical significance.
The interaction between baseline systolic BP and treatment
with GTN vs. no GTN narrowly missed statistical significance
(p = 0.053), with increasing baseline BP associated with
a tendency toward improved functional outcome in the
presence of GTN. This may suggest that modest lowering
of elevated BP in the context of thrombolysis may be
beneficial, perhaps priming patients for earlier thrombolysis
without the need for intravenous BP lowering, whilst also
reducing the risk of potential haemorrhagic complications.
This is line with the ENCHANTED-BP trial demonstrating
less intracranial bleeding in those treated with intensive BP
lowering vs. standard BP lowering, although there was no
effect on functional outcome at 90 days (5). The present
study also demonstrated that treatment with GTN in those
with a baseline systolic BP <140 mmHg was associated with
a tendency toward worse functional outcome at 90 days.
BP lowering in this group may have compromised cerebral
blood flow, extending the ischaemic core resulting in worse
clinical outcomes. Therefore, this approach should be avoided
in those with systolic BP <140 mmHg in the context of
reperfusion therapies.
The strengths of this analysis include the ability to assess
treatment effects at an individual patient level across the included
trials and a high proportion of available outcome data. However,
there are limitations. First, the timing of thrombolysis and
thrombectomy was not recorded in the trials. In RIGHT and
RIGHT-2, randomization to GTN vs. no GTN occurred in the
ambulance prior to hospital and therefore reperfusion therapies.
In ENOS, the relationship between time of randomized treatment
administration and thrombolysis is less clear. We attempted
to address this by assessing those participants randomized
within 6 h of symptom onset separately, as in this group the
randomized treatment is likely to have been received in close
proximity to thrombolysis. Second, we do not have angiographic
data on the proportion of patients with a confirmed large
vessel occlusion at baseline, nor the recanalisation rate on any
subsequent imaging. We were therefore unable to ascertain
whether GTN was safe and efficacious in this population,
or whether GTN had an effect based upon recanalisation
status. Third, data regarding other BP lowering medications
administered in relation to reperfusion therapies were not
available. Such additional medication may have attenuated
any treatment effect of GTN. Last, all included trials were
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FIGURE 1 | Acute ischaemic stroke patients who underwent reperfusion strategies. Distribution of mRS at day 90 by GTN vs. no GTN: adjusted OR 0.94, 95% CI
0.72–1.23, p = 0.65. CI, confidence interval; GTN, glyceryl trinitrate; mRS, modified Rankin Scale; OR, odds ratio.
FIGURE 2 | Acute ischaemic stroke patients who underwent reperfusion strategies and randomized to GTN vs. no GTN within 6 h of onset. Distribution of mRS at day
90 by GTN vs. no GTN: adjusted OR 0.81, 95% CI 0.56–1.18, p = 0.27. CI, confidence interval; GTN, glyceryl trinitrate; mRS, modified Rankin Scale; OR, odds ratio.
performed by the same group and unfortunately included very
few participants treated with thrombectomy. The ongoing MR
ASAP trial in the Netherlands is assessing the use of a single
GTN patch in the ambulance with a particular focus on patients
with large vessel occlusions, adding vital data on this population
(ISCRTN:99503308) (21).
In summary, this individual patient data meta-analysis has
demonstrated that transdermal GTN is safe in patients with
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FIGURE 3 | Forest plot of effect on mRS at day 90 in pre-defined subgroups for acute ischaemic stroke patients who underwent reperfusion strategies by GTN vs. no
GTN. Unadjusted ordinal logistic regression for mRS at day 90 with interaction between subgroup and GTN vs. no GTN. BP, blood pressure; CI, confidence interval;
ENOS, Efficacy of nitric oxide in stroke trial; GTN, glyceryl trinitrate; LACS, lacunar syndrome; mRS, modified Rankin scale; NIHSS, National Institutes for Health
Stroke Scale; OCSP, Oxfordshire community stroke project; OTR, onset to randomization; PACS, partial anterior circulation syndrome; POCS, posterior circulation
syndrome; RIGHT, Rapid intervention with glyceryl trinitrate in hypertensive stroke trial; TACS, total anterior circulation syndrome.
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acute ischaemic stroke undergoing reperfusion therapies (>99%
thrombolysis), but does not influence functional outcome at 90
days. GTNwithin 6 h of stroke onset in this setting was associated
with tendencies toward improved functional outcome and fewer
haemorrhagic complications. The timing of BP lowering in the
context of reperfusion therapies warrants further investigation,
particularly in regard to thrombectomy and recanalisation status,
in ongoing and future studies.
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